Tag: Compugen
BMS, Compugen to trial COM701 Opdivo combo in advanced solid tumors
US biopharma company Bristol-Myers Squibb (BMS) has entered into a clinical collaboration with Compugen to evaluate the combination of its cancer drug Opdivo (nivolumab) with ... Read More
Compugen kickstarts phase 1 trial of cancer immunotherapy COM701
Israeli pharma company Compugen has dosed the first patient in the phase 1 clinical trial which is evaluating the company’s cancer immunotherapy antibody COM701 in ... Read More